A biomarker study to measure proteasome activity in peripheral blood mononuclear cells as an indicator of susceptibility to bortezomib-induced severe neurological adverse events in patients with multiple myeloma
Latest Information Update: 04 Dec 2015
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Biomarker
Most Recent Events
- 04 Dec 2015 New trial record